Delphi Consensus on the Use of Fenofibrate as Systemic Therapy for the Prevention of Diabetic Retinopathy Progression
Journal of Diabetes · 2026
DOI: 10.1111/1753-0407.70193 ↗Kurz gefasst
Delphi-Studie in der Zeitschrift Journal of Diabetes, 2026. Verfasst von Richard C O'Brien und 9 weiteren Autor:innen. Beteiligte Einrichtung: Austin Clinical School, Melbourne Medical School, University of Melbourne, Melbourne, Australia. Hauptthemen laut MEDLINE: Diabetic Retinopathy, Fenofibrate, Hypolipidemic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Abbott Products Operations AG.
Abstract (Originalsprache)
Background
Diabetic retinopathy remains a leading cause of preventable blindness worldwide, yet screening and management practices vary widely. Evidence suggests that systemic therapies, including fenofibrate, may slow diabetic retinopathy progression, but their use is inconsistent across clinical settings. This study aimed to establish an evidence‐informed consensus among endocrinology experts on the screening, diagnosis, and treatment of diabetic retinopathy, with a particular focus on recommendations for the use of systemic therapy to prevent disease progression.
Methods
A modified three‐round Delphi process was conducted with 19 endocrinology experts from diverse geographic regions. A core panel of 10 experts and an extended panel of 9 reviewed and rated 19 evidence‐based statements. Consensus was defined as > 75% agreement.
Results
All 19 statements achieved consensus, with 14 receiving > 80% agreement. The panel endorsed frequent diabetic retinopathy screening based on diabetes type and risk level, early initiation of fenofibrate in patients with mild to moderate non‐proliferative diabetic retinopathy, and continued therapy to sustain retinal protection. Fenofibrate was recognized for its pleiotropic effects, and the experts agreed that the transient rise in serum creatinine with fenofibrate is not indicative of renal damage and should not prompt discontinuation.
Conclusions
This consensus highlights the need for multidisciplinary care, coordinated pathways, and patient education in diabetic retinopathy care. It also offers unified, evidence‐informed recommendations for endocrinologists for the early initiation of fenofibrate to reduce diabetic retinopathy progression. While further studies are needed, these findings offer a practical framework for improving diabetic retinopathy management globally.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Austin Clinical School, Melbourne Medical School, University of Melbourne, Melbourne, Australia.
- Diabetes and Metabolism Unit, Department of Internal Medicine, Alexandria University, Alexandria, Egypt.
- Department of Endocrinology and Metabolism, Sir Run Run Shaw Hospital of Zhejiang University, Hangzhou, China.
- Department of Endocrinology and Diabetes, Dubai Hospital, Dubai Academic Health Cooperation, Dubai, UAE.
- Department of Endocrinology and Metabolism, Xi'an International Medical Center Hospital of Northwest University, Xi'an, Shaanxi, China.
- Department of Internal Medicine, School of Medicine, Alanya Alaaddin Keykubat University, Antalya, Turkey.
ORCID-Profile: Richard C O'Brien, Qiuhe Ji, Patricio Lopez-Jaramillo
Förderung
- Abbott Products Operations AG
Zitieren
APA
O'Brien, R. C., Abdallah, K., Dong, X., Hassanein, M., Ji, Q., Keskek, S. O., Lopez-Jaramillo, P., Mehta, R., Raef, H., & Tan, K. (2026). Delphi Consensus on the Use of Fenofibrate as Systemic Therapy for the Prevention of Diabetic Retinopathy Progression. Journal of Diabetes. https://doi.org/10.1111/1753-0407.70193
Vancouver
O'Brien RC, Abdallah K, Dong X, Hassanein M, Ji Q, Keskek SO, et al. Delphi Consensus on the Use of Fenofibrate as Systemic Therapy for the Prevention of Diabetic Retinopathy Progression. Journal of Diabetes. 2026. doi:10.1111/1753-0407.70193
BibTeX
@article{OBrien2026,
author = {O'Brien, Richard C and Abdallah, Khalifa and Dong, Xuehong and Hassanein, Mohamed and Ji, Qiuhe and Keskek, Sakir Ozgur and Lopez-Jaramillo, Patricio and Mehta, Roopa and Raef, Hussein and Tan, Kevin},
title = {Delphi Consensus on the Use of Fenofibrate as Systemic Therapy for the Prevention of Diabetic Retinopathy Progression},
journal = {Journal of Diabetes},
year = {2026},
doi = {10.1111/1753-0407.70193}
}
EUVIMED